<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8148">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01801904</url>
  </required_header>
  <id_info>
    <org_study_id>PACER</org_study_id>
    <secondary_id>2010-024490-39</secondary_id>
    <nct_id>NCT01801904</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer</brief_title>
  <acronym>PACER</acronym>
  <official_title>A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera G. Rummo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if panitumumab is active enough to warrant
      comparative studies in patients with metastatic colorectal cancer that has progressed after
      treatment with cetuximab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>number of patients alive and without disease progression</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>progression of disease within 2 months from registration according to RECIST criteria, and death for any cause within 2 months from registration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>up to 40 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response assessed per patients at weeks 8,16,24,32,40 and every 3 months thereafter, using RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade toxicity per patient</measure>
    <time_frame>every 2 weeks for up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>worst grade toxicity (according to Common Terminology Criteria for Adverse Events version 3) per patient</description>
  </secondary_outcome>
  <other_outcome>
    <measure>gene expression on tumor tissue</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>exploratory analysis of tumor-tissue for biological or genomic determinants of outcome (N-ras, BRAF and P13K mutation status, EGFR and PTEN expression status</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity</description>
    <arm_group_label>Panitumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic diagnosis of metastatic colorectal adenocarcinoma

          -  A wild-type tumor KRAS gene determined from tumor DNA

          -  Failure from previous treatment with fluoropyrimidine, oxaliplatin and irinotecan.
             Patients may or may not have been treated with bevacizumab.

          -  Documented disease progression following a treatment with cetuximab in patients who
             showed either an objective response after 8 weeks or stable disease after 16 weeks of
             cetuximab treatment.

          -  Age at least 18 years

          -  ECOG Performance Status 0-2

          -  Neutrophils at least 1,500 mm3, platelets at least 100,000 mm3, and hemoglobin at
             least 9 g/dL

          -  Bilirubin level less than 1.5 times ULN

          -  AST (SGOT) and ALT (SGPT) not greater than 2.5 times ULN (or 5 times ULN in presence
             of liver metastasis)

          -  Serum creatinine less than 1.5 times ULN

          -  Effective contraception, if the risk of conception exists

          -  Life expectancy at least 3 months

          -  Written informed consent

        Exclusion Criteria:

          -  Symptomatic brain metastasis

          -  Interstitial pneumonitis or pulmonary fibrosis

          -  Any other malignancies within 5 years (except for adequately treated carcinoma in
             situ of the cervix or non melanoma skin cancer)

          -  Chemotherapy, radiotherapy or immunotherapy within the past 4 weeks

          -  Any unstable systemic disease (including active infections, any significant hepatic,
             renal or metabolic disease), metabolic dysfunction, physical examination finding, or
             clinical laboratory finding that contraindicates the use of study drugs or render the
             patient at high risk from treatment complications

          -  Subject pregnant or breast feeding, or planning to become pregnant within 6 months
             after the end of treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Daniele, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Sanitaria Rummo, Benevento, Division of Medical Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute Naples, Italy;  Director Clinical Trials Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second University of Naples, Italy; Chair of Medical Statistics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Gasbarrini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit√† Cattolica del S. Cuore, Policlinico Gemelli, Roma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giacomo Carteni', M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Antonio Cardarelli, Napoli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <phone>+39 081 5903571</phone>
    <email>francesco.perrone@usc-intnapoli.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Carmela Piccirillo, M.D.</last_name>
    <phone>+39 081 5903615</phone>
    <email>marilina.piccirillo@usc-intnapoli.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Rummo</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casa Sollievo Sofferenza</name>
      <address>
        <city>S. Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 3, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cetuximab-refractory</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
